CLL1 CAR-T

N/A

Report date: 2025/03/14 16:24:54

Base Information

Drug NameCLL1 CAR-T
Drug Alias Nameautologous anti-CLL1 CAR T-cell therapy (Zhejiang University)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionC-Type lectin domain family 12 member A modulators
TargetsC-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesZhejiang University
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A